Evommune Inc share price logo

Evommune Inc Share Price

NYSE: EVMN

Small Cap

$20.97

-2.48

(-10.58%)

as on

Evommune Inc Stock Performance

as on March 25, 2026 at 6:59 am IST

  • Day's Low

    Day's High

    $20.64
    $23.04
    downward going graph

    1.57%

    Downside

    9.87%

    Upside

    downward going graph

  • 52 Week's Low

    52 Week's High

    downward going graph

    100.00%

    Downside

    -100.00%

    Upside

    downward going graph

Evommune Inc share price movements today

Previous Close
$23.45
Open
$22.81
Volume
515.8K
Day's Low - High
$20.64 - $23.04

Evommune Inc Historical Returns

1 Month Return
-21.47 %
3 Month Return
+ 33.31 %
1 Year Return
0 %
3 Year Return
0 %
5 Year Return
0 %

Evommune Inc Stock Fundamentals & Key Indicators

Check Evommune Inc market cap, PE, PB, PEG ratios, dividend yield, and other key fundamental indicators.

Market Cap

$735.5M

EPS (TTM)

-2.7814

Dividend Yield

0.00%

PE Ratio (TTM)

0

PEG Ratio

0

Return On Equity TTM

-54.42%

Evommune Inc vs Peer Comparison

Compare market cap, revenue, PE, and other key metrics of Evommune Inc with its industry peers.

Company
Analyst View
Market Cap
5 Years Return %PE RatioProfit Margin %
Evommune Inc image
Evommune Inc
NA$735.5MNANA0.00%
Alnylam Pharmaceuticals, Inc. image
Alnylam Pharmaceuticals, Inc.
BUY$41.4B126.75%133.418.45%
Vertex Pharmaceuticals Incorporated image
Vertex Pharmaceuticals Incorporated
BUY$115.3B112.49%29.6832.94%
Beone Medicines Ltd image
Beone Medicines Ltd
NA$31.6BNA1115.37%
Regeneron Pharmaceuticals, Inc. image
Regeneron Pharmaceuticals, Inc.
BUY$77.5B58.91%17.6731.41%

Evommune Inc Stock’s Investor Sentiment and Interest

Search interest for Evommune Inc Stock has decreased by -64% in the last 30 days, reflecting a downward trend in search activity.

Time period: to

Change:-64% versus previous 30 day period

Evommune Inc Quarterly Profit & Loss

All numbers in Millions USD

Mar 2024
Sep 2024
Dec 2024
Mar 2025
Sep 2025
Total Revenue
7
-
-
3
10
Gross Profit
6
-
-
2
9
Operating Income
-3
-16
-18
-15
-13
EBITDA
-2
-
-18
-14
-12
Interest Expense
0
-
-
0
-
Depreciation
-
0
0
-
0
Income Before Tax
-2
-15
-18
-14
-12
Income Tax Expense
-
-
-
-
-
Net Income
-2
-15
-18
-14
-12
Net Profit Margin
-39.77%
0.00%
0.00%
-485.23%
-124.75%

Evommune Inc Annual Profit & Loss

All numbers in Millions USD

Dec 2023
Dec 2024
Dec 2025
Total Revenue
5
7
13
Gross Profit
4
5
11
Operating Income
-37
-70
-81
EBITDA
-32
-65
-79
Interest Expense
0
0
0
Depreciation
-
-
-
Income Before Tax
-34
-66
-68
Income Tax Expense
-
-
-
Net Income
-34
-66
-68
Net Profit Margin
-681.06%
-954.40%
-529.77%

Evommune Inc Quarterly Cash Flow

All numbers in Millions USD

Jun 2024
Sep 2024
Dec 2024
Mar 2025
Jun 2025
Sep 2025
Dec 2025
Net Income
-27
-15
-18
-14
-13
-12
-28
Operating Cash Flow
-8
-26
-22
-23
-26
-9
-16
Investing Cash Flow
10
-
-11
13
18
-23
-122
Financing Cash Flow
0
0
24
0
64
0
156
Change in Cash
-
-16
-1
5
56
-35
17

Evommune Inc Annual Cash Flow

All numbers in Millions USD

Dec 2024
Dec 2025
Net Income
-66
-68
Operating Cash Flow
-58
-76
Investing Cash Flow
-3
-115
Financing Cash Flow
49
220
Change in Cash
-12
27

Insights on Evommune Inc

Insights help you understand the recent movement of the company's critical parameters, giving you an overall view of the company.

  • imgPOSITIVE IMPACT

    Price Rise

    img

    In the last 3 months, EVMN stock has moved up by 33.3%

About Evommune Inc

Evommune, Inc. is a clinical-stage biotechnology company developing therapies that target key drivers of chronic inflammatory diseases. Its initial clinical development programs are focusing on chronic spontaneous urticaria (CSU), atopic dermatitis (AD) and ulcerative colitis (UC). Its product candidates include EVO756 and EVO301. The Company's advanced clinical-stage product candidate, EVO756, is a potent and highly selective oral small molecule antagonist of MRGPRX2, a receptor predominantly found on mast cells and peripheral sensory neurons, which is initially being evaluated in Phase II trials for the treatment of CSU and AD. The Company's second clinical-stage product candidate, EVO301, is a long-acting fusion protein consisting of an IL-18 binding protein (BP) and an anti-serum albumin Fab-associated (SAFA) domain, which is being evaluated in Phase II trials for the treatment of AD and UC.
OrganisationEvommune Inc
Headquarters1841 Page Mill Road, Palo Alto, CA, United States, 94304
CEOMr. Luis C. Pena
E-voting on sharesClick here to vote

Key Management of Evommune Inc

Name

Title

Dr. Jeegar Patel Ph.D.

Chief Scientific Officer

Ms. Janice Drew M.P.H.

Chief of Development Operations

Dr. Lou Sehl Ph.D.

Senior Vice President of Technical Operations

Mr. J. Mark Jackson M.D.

Senior Vice President of Clinical Development

Mr. Luis C. Pena

Founder, President, CEO & Director

Mr. Kyle Carver CPA, M.B.A.

Chief Financial Officer

Mr. Gregory S. Moss Esq.

Chief Business & Legal Officer, Corporate Secretary and Chief Compliance Officer

Dr. Eugene Andrew Bauer M.D.

Co-Founder, Chief Medical Officer & Director

Dr. Daniel J. Burge M.d.

Senior Vice President of Clinical Development

FAQs

What is Evommune Inc share price today?

Evommune Inc share price today is $20.97 as on at the close of the market. Evommune Inc share today touched a day high of $23.04 and a low of $20.64.

What is the 52 week high and 52 week low for Evommune Inc share?

Evommune Inc share touched a 52 week high of $ on and a 52 week low of $ on . Evommune Inc stock price today i.e. is closed at $20.97,which is -Infinity% down from its 52 week high and Infinity% up from its 52 week low.

What is Evommune Inc's market capitalisation today?

Evommune Inc market capitalisation is $0.00T as on .

How to invest in Evommune Inc Stock (EVMN) from India?

  1. Step 1: Open a free US stocks account on INDmoney App and transfer your Rupees into Dollars to your INDmoney US stocks account. For a step by step instruction, check How to Transfer Money to Your US Stocks Account .
  2. Step 2: Search for Evommune Inc on INDmoney app. Click on Buy button. You can invest as low as $1.5 in Evommune Inc Shares that will get you 0.0715 shares as per Evommune Inc share price of $20.97 per share as on March 25, 2026 at 1:29 am IST.

What is the minimum amount required to buy Evommune Inc Stock (EVMN) from India?

Indian investors can start investing in Evommune Inc (EVMN) shares with as little as ₹93.734 or $1 (as of ) using the INDmoney app.
For example: If you want to invest $10 or ₹937.34 in Evommune Inc stock (as per the Rupee-Dollar exchange rate as on ). Based on Evommune Inc share’s latest price of $20.97 as on March 25, 2026 at 1:29 am IST, you will get 0.4769 shares of Evommune Inc. Learn more about fractional shares .